micro-community-banner
 
Profile Image
  • Image/Video
  • Saved

2w
The effectiveness and perceived value of feedback used in cardiac arrest simulation education: a mixed-method systematic review - PubMed

The effectiveness and perceived value of feedback used in cardiac arrest simulation education: a mixed-method systematic review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41074008/

Feedback in cardiac arrest simulation education is just as important as the simulation itself and should align with the learner's educational objectives. There is a notable underreporting of integral non-technical...

This mixed-method review found that both human and device-based feedback improve cardiac arrest simulation performance. Objective, device-based feedback is preferred, but non-technical aspects and qualitative perspectives remain underexplored in current research.

Profile Image
  • Saved

3w
Currently managed US prevalence of cutaneous venous malformations (cVMs): a nationally representative, retrospective, real-world, subject-blinded, physician-observational probability study - PubMed

Currently managed US prevalence of cutaneous venous malformations (cVMs): a nationally representative, retrospective, real-world, subject-blinded, physician-observational probability study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41057921/

While cVM is rare, it affects a substantial number of individuals across age groups in the U.S. These findings underscore the need for improved access to care and the development...

A nationally representative physician survey estimated approximately 194,000 U.S. patients with cutaneous venous malformations, revealing a 0.06% prevalence and emphasizing unmet therapeutic needs, diagnostic challenges, and the lack of approved treatments for this rare vascular anomaly.

Profile Image
  • Saved

4w

Did you know? A Bulgarian study found 79 of 142 ADR reports on cardiovascular drugs were serious. Sartans like valsartan were linked to melanoma and other cancers within 2–5 years. Statins and ACE inhibitors also showed alarming reactions like MI, heart failure, and arrhythmia—calling for more vigilant prescribing and follow-up.

Could awareness of serious ADRs like cancer from sartans influence your approach to monitoring patients and selecting cardiovascular treatments?

NCCN Guidelines

Could awareness of serious ADRs like cancer from sartans influence your approach to monitoring patients and selecting cardiovascular treatments?

Profile Image
  • Saved

4w
Background Image DesktopBackground Image Mobile

Genetic mutations were found in 71% of arrhythmia patients with cardiac devices. Variants in TMEM43 and titin (TTN) are linked to poor CRT outcomes. Personalised selection, such as using transvenous ICDs for ACM, improves prognosis and care.

Leverage genetics to tailor cardiac care

Profile Image
  • Saved

1mo
case study

 

Patient background

A 68-year-old man with a history of hypertension and type 2 diabetes presents with acute decompensated heart failure, reporting progressive dyspnea, two-pillow orthopnea, and bilateral lower extremity edema. He has a 5-year history of chronic heart failure with reduced ejection fraction (HFrEF) but has only been on loop diuretics for the past year, with no other components of guideline-directed medical therapy (GDMT) prescribed. His family history is notable for premature cardiovascular deaths in first-degree relatives.

Assessment and diagnosis 

On exam, the patient had diminished breath sounds, bilateral basal crackles, elevated jugular venous pressure, and pitting edema to the mid-shins. His oxygen saturation was 95% on room air. Echocardiogram revealed a reduced left ventricular ejection fraction (LVEF) of 25%, confirming HFrEF. Laboratory evaluation showed serum creatinine 1.4 mg/dL, eGFR 48 ml/min/1.73m², and potassium 4.2 mEq/L. Following treatment with intravenous loop diuretics, he achieved near-euvolemia and maintained a stable systolic BP of 115 mmHg without requiring inotropic support. Final diagnosis: acute on chronic HFrEF. Plans were made to initiate GDMT during hospitalization and to schedule outpatient follow-up for reassessment and titration.

  1. How do you initiate and optimize guideline-directed medical therapy in acute decompensated heart failure?
  2. How do you integrate newer agents like SGLT2 inhibitors into established GDMT sequencing in your practice?
Profile Image